Results 101 to 110 of about 6,174 (184)

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor [PDF]

, 2017
et al,, Tan, Benjamin R
core   +2 more sources

Exceptional case of tumor lysis syndrome following Encorafénib-Binimétinib therapy for metastatic melanoma

EJC Skin Cancer
We report a case of tumor lysis syndrome (TLS) occurring 48 h after initiation of targeted therapy with Encorafénib and Binimétinib in a patient with an extensive metastatic melanoma harboring a BRAF V600E mutation.
Adielle Abecassis, Laura Perray, Rafaele Molinier, Safa Idoudi, Helene Kemp, Céleste Lebbé, Laetitia Vercellino, Emilien Ezine, Marie Fournier   +8 more
doaj   +1 more source

Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma [PDF]

Background: The impact of the order of treatment with checkpoint inhibitors or BRAF/MEK inhibitors on the development of brain metastases in patients with metastatic unresectable BRAFV600-mutant melanoma is unknown. The SECOMBIT trial examined the impact
Arance, Ana, Ascierto, Paolo A., Bulgarelli, Jenny, Casula, Milena, Cossu, Antonio, De Placido, Sabino, Del Vecchio, Michele, Dummer, Reinhard, Ferraresi, Virginia, Ferrucci, Pier Francesco, Giannarelli, Diana, Gogas, Helen, Gonzalez-Cao, Maria, Grimaldi, Antonio M., Guida, Michele, Guidoboni, Massimo, Helgadottir, Hildur, Lebbé, Céleste, Maiello, Evaristo, Mallardo, Domenico, Mandalà, Mario, Melero, Ignacio, Minisini, Alessandro Marco, Palmieri, Giuseppe, Paone, Miriam, Piccin, Luisa, Piccinini, Claudia, Pisano, Marina, Quaglino, Pietro, Queirolo, Paola, Richtig, Erika, Rutkowski, Piotr, Sanmamed, Miguel F., Sileni, Vanna Chiarion, Spagnolo, Francesco, Tucci, Marco, Vitale, Maria Grazia   +36 more
core   +1 more source

Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma [PDF]

Modern advancements in targeted therapy and immunotherapy have significantly improved survival outcomes for advanced melanoma; however, there remains a need for novel approaches to overcome disease progression and treatment resistance.
Abdulla, Farah, Adeyelu, Tolulope, Ansstas, George, Butt, Omar, Elliott, Andrew, Morecroft, Renee, Nassief, George, Park, Soo, Phillipps, Jordan, Vanderwalde, Ari, Zhou, Alice   +10 more
core   +2 more sources

Abstracts of the 18th SCWD Conference, 11‐13 December 2025 in Rome/Italy

JCSM Communications, Volume 9, Issue 1, January/June 2026.
wiley   +1 more source

Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAFV600-mutant melanoma in Spain: the BECARE (GEM-2002) trial [PDF]

Immune checkpoint inhibitors; Melanoma; MutationInhibidores de puntos de control inmunitario; Melanoma; MutaciónInhibidors de punts de control immunitari; Melanoma; MutacióPurpose: Combined BRAF/MEK inhibition with encorafenib (E) plus binimetinib (B ...
García Galindo , Regina, Gutierrez Sanz, Lourdes, MUÑOZ COUSELO, EVA, Sanchez Mauriño, Pedro, Sequero-Lopez, Silvia, Serrano Domingo, Juan Jose, SORIA RIVAS, AINARA   +6 more
core   +1 more source

SEOM-GEM clinical guidelines for cutaneous melanoma (2023) [PDF]

Melanoma; Staging; Targeted therapyMelanoma; Estadificación; Terapia dirigidaMelanoma; Estadificació; Teràpia dirigidaCutaneous melanoma incidence is rising. Early diagnosis and treatment administration are key for increasing the chances of survival. For
Arance Fernández, Ana Mª, Berciano Guerrero, Miguel Angel, Campos, Begoña, Marquez-Rodas, Ivan, MUÑOZ COUSELO, EVA, Rodríguez Moreno, Juan F.   +5 more
core   +1 more source

MEK + CDK4 a regimen for non-BRAF V6000 melanoma [PDF]

, 2015
Jeff Sosman
core   +1 more source

Gyógyítható lesz-e a melanoma? Perspektívák a melanoma kezelésében = Will melanoma be curable? Perspectives in melanoma therapy [PDF]

, 2017
Baltás, Eszter, Gyulai, Rolland, Lengyel, Zsuzsanna   +2 more
core   +1 more source

Sweet syndrome in a patient receiving encorafenib and binimetinib therapy for malignant melanoma

JAAD Case Reports
Myiah Quach, BS, John P. Antonelli, BS, Charlotte LaSenna, MD, Mackenzie Asel, MD, Jennifer Pleva, DNP, Vincent T. Ma, MD   +5 more
doaj   +1 more source